New Valley University
Asa Night's Asmaa
Type 2 diabetes mellitus (DM) has adopted a top priority as it is a disease with an increasing prevalence. The number of people living with DM has increased more than fourfold over the past 40 years to more than 460 million people today
Type 2 Diabetes
HBA1C
Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides
Urine analysis and urinary albumin-to-creatinine ratio
Serum creatinine and estimated glomerular filtration rate
Complete blood count
Thyroid-stimulating hormone
Serum iron, TIBC, Transferrin saturation and serum ferritin if needed
Electrocardiography (ECG)
Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound
Arterial duplex ultrasound of both lower limbs
Random blood glucose
AST, ALT, albumin
NA
All-cause mortality rates have declined substantially in several high-income countries, including England. A diversification in non-fatal conditions in people with DM has also been reported. This is attributable to broader, non-vascular conditions. Due to increasing longevity among people with type 2 DM with increasing and diversifying multimorbidity in them, the health needs of people with Type 2 DM are therefore likely to be broad, and complex. Finding multimorbidity (two or more chronic conditions) is common in people with Type 2 DM and increasing, but the comorbidity profiles of people with T2DM vary substantially. Many studies have primarily focused on identifying multimorbidity patterns in the general population. The understanding of multimorbidity patterns and composition of specific comorbidities in people with DM, and how this varies across patient groups and during the course of the disease, is limited. Further knowledge of this could provide insight into providing more holistic and more personal approaches to clinical guideline development, care pathways, and secondary prevention.
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 288 participants |
| Masking : | NONE |
| Primary Purpose : | SCREENING |
| Official Title : | Comorbidities in Type 2 Diabetes Mellitus: An Observational Study in Kharga City, New Valley Governate, Egypt |
| Actual Study Start Date : | 2023-11-15 |
| Estimated Primary Completion Date : | 2024-12-30 |
| Estimated Study Completion Date : | 2025-03-30 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years to 90 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
New Valley University
Kharga Oasis, Egypt, 72511